key: cord-0914765-kz15x6za authors: Qaderi, Kowsar; Golezar, Mohammad Hossein; Mardani, Abbas; Mallah, Manthar Ali; Moradi, Bagher; Kavoussi, Hossein; Shamsabadi, Ahmadreza; Golezar, Samira title: Cutaneous adverse reactions of COVID‐19 vaccines: A systematic review date: 2022-03-08 journal: Dermatol Ther DOI: 10.1111/dth.15391 sha: b46a20d7ea9aa6eb79f7ebf2d963190ccb8f81bf doc_id: 914765 cord_uid: kz15x6za Numerous vaccines are under clinical development and implementation for the prevention of severe course and lethal outcomes of coronavirus disease 2019 (COVID‐19). This systematic review aims to summarize and integrated the findings of studies regarding cutaneous side effects of COVID‐19 vaccines. This systematic review conducted by searching the scientific databases of PubMed, Scopus, Science direct, and Web of knowledge from the beginning of the COVID‐19 to May 10, 2021. Articles were reviewed and analyzed based on the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses checklist. Seventeen studies on cutaneous side effects of COVID‐19 vaccines were included after the screening of search results based on to the eligibility criteria. The results showed that the most common injection site reactions and delayed large local reactions, arising from all vaccine types, were redness/erythema (39%), followed by: itchiness (28%), urticarial rash (17%) on the neck, upper limbs, and trunk, morbilliform eruptions (6.5%), Pityriasis rosea (3%), swelling, and burning, and so forth. Most cutaneous reactions occurred in women (84%), and middle‐aged people, after the first dose of vaccine, with the onset ranged from 1 to 21 days after vaccination. In addition, cutaneous reactions were generally self‐limiting, and needed little or no therapeutic intervention, that were not regarded as a barrier to injecting a second dose. In conclusion, severe cutaneous side effects are very rare and approved vaccines have satisfactory safety profiles. Therefore, mild or moderate cutaneous reactions should not discourage people from vaccination. In certain groups such as patients with allergies and a history of local injection reactions, pre‐vaccination counseling and assurance, also use of appropriate medications may be helpful. However, more studies are needed to investigate the side effect profile of all COVID‐19 vaccines. The pandemic of coronavirus disease 2019 (COVID-19) has prompted the fast development and licensing of vaccinations against the pathogen responsible-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1 Vaccination candidates were created by more than 100 businesses and universities throughout the world, utilizing both well-established and more experimental vaccine platforms. 2 Protein subunit vaccines have not yet been included into mass immunization campaigns, although they may do so soon. Many nations lack access to COVID-19 vaccines, despite the fact that certain high-income countries have already immunized the vast majority of their citizens. Because trade names may differ locally, we will always refer to vaccinations by their generic names. More than a year later, a range of efficacious and safe COVID- 19 vaccinations are now being administered across the world. Currently licensed vaccines use nucleic acid-based vaccination platforms, such as messenger ribonucleic acid (mRNA), viral vector platforms (using various adenovirus strains), and inactivated virus. Antiviral immunity is induced effectively by humoral and cellular immune responses. Apart from those that employ live attenuated virus, most vaccination types require many doses and/or adjuvants to effectively stimulate the innate immune system, which then elicits adaptive immunological responses. DAMPs activate pattern recognition receptors (PRRs), including toll-like receptors (TLRs), which mediate immunogenic effects. 3 Nucleic acids (including mRNA) are danger-associated molecular patterns (DAMPs) that activate PRRs, including TLRs, which mediate immunogenic effects. As a result, the COVID-19 mRNA vaccines now available do not require adjuvants. 4 Although induction of specific and nonspecific skin eruption due to SARS-CoV-2 infection are rare, but in a small number of individuals, SARS-CoV-2 infections can cause vesicular, urticarial, and chilblain-like eruptions. 5, 6 Similar pathophysiological responses might be detected after an immunogenic challenge with a comparable vaccination. Some cutaneous drug reactions, including the reaction to the vaccine, can be initial manifestation of severe drug reactions that associated with internal organs involvement. 7 Finally, cutaneous adverse drug reactions (ADRs) appear to be common with the administration of COVID-19 vaccinations, and include erythema, swelling, itching, pernio-like lesions, and widespread rashes. 8 Despite the fact that they might be frightening for patients and treating physicians, most clinical studies do not accurately reflect them from a dermatological standpoint. In this systematic review, we want to draw attention to the wide range of possible cutaneous inflammatory responses that might occur during vaccination administration in order to help healthcare providers better understand these individuals. This systematic review aims to summarize and integrate the findings of studies regarding cutaneous side effects of COVID-19 vaccines. This study was a systematic review that was performed by searching the scientific databases of PubMed, Scopus, Science direct, and Web of knowledge for relevant English articles published from the beginning of the COVID-19 to May 10, 2021. Analysis of retrieved articles was performed in four-step selection process of identification, screening, eligibility, and inclusion criteria, based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. We conducted a comprehensive search on the scientific databases using MeSH keywords including: To find more studies, the references in the relevant papers were also followed up. The search was performed by two independent researchers. In the first step, two researchers reviewed the retrieved articles and removed the duplicates. In other steps, the researchers screened the title and abstract of the records and the ineligible studies were removed. Then, the authors surveyed the full-text of the remaining studies based on inclusion and exclusion criteria and the eligible studies were identified. We excluded the articles, which were topic to at least one of the following criteria: • Nonoriginal articles including reviews and editorials • Lack of full text • Abstract papers, articles without obtainable full texts, and conference abstracts. • Clinical trials, which were in progress without yet published results. • COVID-19 no vaccine trials articles • Non-English articles The following information was extracted from full-text articles by three authors: first author (reference); type of study; country of study; population; medical history; type of vaccine; cutaneous manifestations; duration of cutaneous manifestations; mechanism of cutaneous reactions; diagnostic assessment; management; outcomes; and other findings and transferred into a data spread table. These specifications and the corresponding table were designed by three members of our team. In order to eradicate any probable duplication, the selected articles were investigated by other researchers once again. As mentioned formerly, we utilized the PRISMA checklist for evaluation and analyze of articles. The quality and relevance of the articles were investigated by two independent and experienced members. In any case their decisions differed, a third independent researcher confirmed their disagreements. A total of 69 potentially relevant articles were identified through the initial searches. After removing duplicates 58 articles remained, and then 32 articles were excluded by screening titles and abstracts, and the full texts of 26 remaining articles were assessed for eligibility. Finally, 17 studies met the inclusion criteria and were included in this systematic review as Figure 1 shows. The studies and clinical characteristics are summarized in Table 1 . These studies were conducted in different countries, eight case reports from Saudi Arabia, India, Turkey, and United Kingdom, as well as seven case series from Northeast Italy, and Germany and two cross-sectional studies. Our results showed that the most common injection site reactions and delayed large local reactions, arising from all vaccine types, were redness/erythema (39%), followed by: itchiness (28%), urticarial rash (17%) on the neck, upper limbs, and trunk, morbilliform eruptions (6.5%), Pityriasis rosea (3%), and swelling, burning, and so forth. 8, 12, 13 (Numbers are shown in Table 2 ). Most patients showed cutaneous reactions after the first dose of vaccination. 8, 12, 13, [16] [17] [18] Some patients had very rare adverse dermatological reactions after first and second doses. 8, 12, 17 The Majority of adverse reactions were reported after mRNA-based vaccines. 9, [12] [13] [14] 18 The onset and duration of dermatological manifestations were ranged from 1 to 21 days after vaccination except for three reports that reactions appeared within the first hours. 10, 11, 14 Moreover, delayed cutaneous ADRs may occur after several days, either as a primary manifestation or as a flare of a pre-existing inflammatory dermatosis. 22 The cutaneous side effects of the covid-19 vaccines appear to be more common in women (84% of reported cutaneous reaction after COVID vaccination), 8, 9, [11] [12] [13] [14] [15] [16] 19, 21 and diverse age groups; however, most were middle-aged. 8, 12, 13, 15, 16, 19 None of the skin reactions after the first dose of the vaccine prohibited the administration of the second dose except for six subjects that were advised not applying the second dose. 12, 19 Besides, 18 individuals did not plan to receive the second dose. 8 30 Another study reported that pain and erythema are the most frequent cutaneous side effects of all COVID-19 vaccines. 31 Furthermore, a delayed large local reaction also referred to as "COVID arm," which is characterized by erythematous and edematous patch at the local of injection onset at least 4 days or more after vaccination, was reported mainly in mRNA-based vaccines. 8, 32, 33 Although these reactions are self-limiting, topical steroids or oral medications can be applied to alleviate these reactions. 30 Clinicopathological classification can be helpful in the early diagnosis and management of the dermal reactions to mRNA COVID-19 vaccines. 22 Our review findings revealed the cutaneous side effects of COVID-19 vaccines were mostly affected middle-age populations. Similarly, current evidence shows that local injection site reactions are more seen in the younger population compared the older people. 34, 35 Moreover, according to our findings, the most onset of cutaneous manifestation was 1-21 days after vaccination. Because it is currently unclear whether it should be regarded as a risk factor for anaphylaxis, although the timing of onset after exposure is not consistent with a type I Ig-E mediated reaction. 12 A systematic review reported that the most frequent adverse cutaneous reactions occurred within 7 days after injection. 30 Our review focused only on cutaneous side effects of COVID-19 vaccines in real-world settings, but the mentioned systematic review included studies both from vaccines trial and realworld settings that may explain this inconsistent finding. The current review showed that the cutaneous side effects of the covid-19 vaccines appear to be more common in women. The cause is may due to several probable factors. Women show more vigorous immune responses to external antigens than men. Accordingly, numerous researches have been shown that women have more immune responses to vaccines and also experience more side effects. 36, 37 However, the high prevalence of side effects of COVID-19 vaccines among women may reflect reporting bias. Because women constitute the vast majority of the healthcare workforce who were the first group to be vaccinated against COVID-19. In addition, the healthcare workforce is more likely to be visited by physicians. 8, 30 Another justification is that females are sensitive to health situations and skin problems. 38 mediated and initiate within minutes to an hour of vaccination. Delayed cutaneous reactions are typically seen several days after the vaccination. 13 Delayed large local reaction also referred to as "COVID arm," which is characterized by erythematous and edematous patch at the local of injection onset at least 4 days or more after vaccination, was reported mainly in mRNA-based vaccines. 7, 13, 34 The research suggests that T-cell-mediated hypersensitivity reactions have the main role in the onset of these skin lesions. 32, 33 However, the mechanism of possible cutaneous reactions related to COVID-19 vaccines has not yet been elucidated, and any possible allergens have not yet been recognized. However, our review showed that the majority of cutaneous adverse reactions are associated with mRNA-based vaccines, which is consistent with a previous study. 30 Among the various excipients in COVID-19 vaccines, it seems that PEG in mRNA vaccines is one of the suspected causes of allergic reactions. 29 Nevertheless, additional work is required to further dissect the phenomenon and reveal the underlying immunologic mechanism and determine the best suitable vaccine type for individual groups of patients. Herpes zoster infection (VZV reactivation) has been experienced by some patients. 10, 12, 19, 24, 27 COVID vaccination in old patients could lead to VZV reactivation. 10 The current review presents findings on an evolving universal phenomenon and some limitations should be considered. The studies included in this review were mainly case reports and case series, which can make their results challenging. Therefore, future studies with robust designs such as cohorts in this field are needed to provide more accurate findings with more details. In addition, due to potential underreporting of complications, side effects such as cutaneous reactions following COVID-19 vaccination may be more than reported. More clinical trials still are needed to investigate the side effect profile of all COVID-19 vaccines. Cutaneous side effects and allergic reaction is one of the expected complications after any COVID-19 or non-COVID-19 vaccination. Recognizing these reactions can have a key role in vaccine strategy because anxieties about developing reactions can considerably influence people's willingness to receive the first dose or return for a second dose. Injection site reactions are one of the most common cutaneous side effects after COVID-19 vaccines, which most of these reactions are mild or moderate, have no serious consequences, and are usually self-limiting without any interventions. Therefore, these reactions should not discourage people from vaccination. It seems that cutaneous side effects with mRNA-based COVID-19 vaccines are more common; however, the COVID-19 vaccine boundary is growing rapidly and future research results may provide more detailed information. In certain groups such as patients with allergies and a history of local injection reactions, it seems that prevaccination counseling and giving guidance and use of antihistamines and topical medications may benefit. The all authors declare that there is no conflict of interest regarding the publication of this article. The conception and design of the study was contributed by Ahmadreza This article is based on published data, and hence ethical approval is not required. The data that support the findings of this study are available from the corresponding author upon reasonable request. Kowsar Qaderi https://orcid.org/0000-0002-6233-8117 Manthar Ali Mallah https://orcid.org/0000-0003-1037-9440 Bagher Moradi https://orcid.org/0000-0002-3875-2510 COVID-19 vaccine: a comprehensive status report Immunological considerations for COVID-19 vaccine strategies Extracellular RNA as a versatile DAMP and alarm signal that influences leukocyte recruitment in inflammation and infection Synthetic messenger RNA-based vaccines: from scorn to hype Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases SARS-CoV-2, COVID-19, skin and immunology-what do we know so far? Severe cutaneous adverse reactions to drugs. The Lancet Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registrybased study of 414 cases Palms and soles itchiness as a side effect of COVID-19 vaccination Herpes zoster after inactivated COVID-19 vaccine: a cutaneous adverse effect of the vaccine Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction Severe cutaneous adverse reaction following COVID-19 vaccination and immunotherapy: a second hit? Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19 Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination BCG scar local skin inflammation as a novel reaction following mRNA COVID-19 vaccines in two international healthcare workers Skin adverse reactions to novel messenger RNA coronavirus vaccination. A Case Series Diseases Delayed cutaneous hypersensitivity reaction to Vaxzevria (ChAdOx1-S) vaccine against SARS-CoV-2 Clinicopathological features of cutaneous reactions after mRNAbased COVID-19 vaccines A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine Herpes zoster emergence following mRNA COVID-19 vaccine Cutaneous skin manifestation following messenger RNA Moderna SARS-CoV-2 vaccine with dermal hypersensitivity reaction histopathology Cutaneous adverse reactions to covid-19 vaccines: insights from an immuno-dermatological perspective Plantar herpes zoster following heterologous recombinant adenovirus-based COVID-19 vaccine Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: an observational study The art of prevention: COVID-19 vaccine preparedness for the dermatologist Cutaneous adverse effects of the available COVID-19 vaccines COVID-19 vaccines and the skin: the landscape of cutaneous vaccine reactions worldwide Cutaneous adverse reactions to COVID-19 vaccines: insights from an Immuno-dermatological perspective Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2 Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Sex differences in immune responses Sex and gender impact immune responses to vaccines among the elderly Sensitive to infection but strong in defense-female sex and the power of Oestradiol in the COVID-19 pandemic. Front Global Women's Health Localized bullous fixed drug eruption following yellow fever vaccine COVID-19: Allergic reactions to SARS-CoV-2 vaccines Additional supporting information may be found in the online version of the article at the publisher's website.